Bio E公司的Corbevax疫苗或是印度最便宜的疫苗，每剂250卢比

Bio E's Corbevax may be India’s cheapest vaccine at Rs 250 per dose

Bio E公司的Corbevax疫苗或是印度最便宜的疫苗，每剂250卢比

HYDERABAD: Biological E’s recombinant protein Covid-19 vaccine, Corbevax, could well emerge as the most affordable of vaccines in the Indian market once it gets emergency use approval (EUA). Corbevax is slated to be rolled out at a sub-Rs 500 pricing, not for one dose but both the doses, and may even be priced below Rs 400 for two doses. Biological E managing director Mahima Datla had hinted at this in an exclusive interview to TOI earlier, adding the pricing was yet to be finalised.

海得拉巴：一旦获得紧急使用批准(EUA)， Bio E公司的重组蛋白疫苗Corbevax很可能成为印度市场上最廉价的疫苗。Corbevax预计将以低于500卢比的价格推出，不是一剂，而是两剂，甚至两剂的价格可能低于400卢比。Bio E总经理Mahima Datla早些时候在接受《印度时报》独家采访时暗示了这一点，他补充说，价格尚未敲定。

SII’s Covishield is priced at Rs 300 a dose for state governments and Rs 600 a dose for private hospitals, while the corresponding figures for Bharat Biotech’s Covaxn are Rs 400 and Rs 1,200. Russian vaccine Sputnik V has been priced at Rs 995 per jab by Dr Reddy’s Laboratories and will be available only to state and private hospitals.

印度血清研究所的Covishield为邦政府提供的价格是300卢比一剂，为私人医院提供的价格是600卢比一剂，而Bharat Biotech的Covaxn的价格分别是400卢比一剂和1200卢比一剂。俄罗斯疫苗Sputnik V在Reddy博士的实验室标价995卢比，仅供给公立和私立医院。

Corbevax is undergoing phase III trials and with phase I & II trials showing promising results, the Centre has pre-booked 30 crore doses for an advance payment of Rs 1,500 crore or Rs 50 per dose.

Corbevax正在进行第三阶段试验，第一和第二阶段试验显示出有希望的结果，印度政府已经预定了3亿剂疫苗，预付款为150亿卢比，每剂50卢比。

While Biological E has already begun at-risk manufacturing of the vaccine over the past month or so, Datla had expressed confidence that the company would be in a position to begin full-fledged production of 75-80 million doses per month from August.

虽然Bio E公司已经在过去一个月左右的时间里开始了疫苗的生产，但Datla表示，该公司有信心从8月份开始每月生产7500万至8000万剂疫苗。

If the vaccine gets EUA by July-August, the huge volumes that it would churn out could substantially ease the vaccine crunch that has currently hobbled the country’s vaccination drive.

如果该疫苗在7 - 8月前获得EUA，该公司将开始量产，可以大大缓解目前阻碍疫苗接种工作的疫苗短缺问题。

以下是印度时报读者的评论：译者：Jessica.Wu

VPN PATHAK

Govt booking 30 core vials in advance is a good sign. Going through the character of PM Modi, I am sure he will make India not only self reliant in the field of vaccine production but also a major supplier of vaccine in the world. Just wait and see.

政府提前预定了3亿剂，这是一个好迹象。根据莫迪总理的性格，我相信他将使印度不仅在疫苗生产领域自力更生，而且将成为世界上主要的疫苗供应商。拭目以待吧。

News Uncensored Cannot Be Purchased By Politicians

Yes we now self reliant our economy is even worse than Bangladesh something that never happened in history with uneducated idiots in power the country is in a mess

是哦，我们现在自力更生了，我们印度的经济甚至比孟加拉国更糟，这是历史上从未发生过的事，没有受过教育的白痴掌权，国家一团糟

Abraham Varghese

But at the cost of several thousands of people's life

却以牺牲成千上万人的生命为代价

Sanjoy Pandey

This is a very good news.. This is going to solve many problems regarding vaccination.

这是一个非常好的消息。这将解决疫苗接种方面的许多问题。

Shrikanth PK

Great work BE team, all the very best for 100% success.

BE团队，做得好，祝你们取得全面成功。

Girija Samantaray

Great. Best of luck.

太棒了，祝好运

Abhi Wadekar

IndiaN goverment and pharma co are doing their best to save india..

印度政府和制药公司正在竭尽全力拯救印度。

kinginchennai

simple rule in life...you get what you pay for most of the time..

生活中的简单法则：一分钱一分货。

D Vishweshwara Bhat Guest

Once there is approval for sure the pressure for vaccination and coverage will get eased.

一旦获得批准，疫苗接种的压力将得到缓解。

Gurmeet Singh

Very welcome news !! Congratulations Team Bio E !! And very happy to see that Central Govt has booked 30 Crore doses. We seem to have learnt our lessons.

非常受欢迎的消息!!

祝贺Bio E团队!!

很高兴看到印度政府已经订购了3亿剂。我们似乎已经吸取了教训。

Appachu Bellathanda

Good news. Let's pray for their early success.

好消息。祈祷他们早日成功吧。

Giant Frog

Lets see if they walk the talk.

让我们看看他们能否说到做到。

News Uncensored Cannot Be Purchased By Politicians

They only talk and walk nothing else

他们只会说，不会做

Murthy B

Corbevax seems promising! With this, GoI should rethink on procuring Pfizer vaccine.

Corbevax似乎很有希望!

有了这个，印度政府应该重新考虑是否仍采购辉瑞疫苗。

Hitesh Maniar

Nice….

很好

Aslam Khan

Superb

太棒了

Guptan Veemboor

The most important thing is whether this vaccine is effective in controlling the Indian variant Delta which is the prominent virus now spreading in India.

最重要的是，这种疫苗是否能有效控制印度变种，这是目前在印度传播的主要病毒。

but it is still not approved

仍未获得批准

Citizen

money making time , hospitals made huge business for past one year ,now it's turn of pharm companies to do business ,thanks to corona

多亏了新冠病毒，在过去的一年里，印度医院赚了很多钱，现在轮到制药公司发财了

sushil dubey

It's too early to quote sub 500 INR.

现在说价格低于500卢比还为时过早。